CureMetrix

10/08/2026

Your mammogram may show more than you realize.
Swipe to learn what to ask for at your next screening mammogram.

.

10/01/2026

October is Breast Cancer Awareness Month, an important reminder to schedule your routine screening mammogram.

When you schedule or check in, ask one more question: “Do you offer cmAngio?” 💗

cmAngio is the first and only FDA-cleared software to identify and measure Breast Arterial Calcifications (BAC) using the same screening mammogram images already being taken. No additional imaging, radiation, or appointment.

Your mammogram can show more. Ask for Angio. cmAngio.

Because BAC Matters.

Learn more here: www.AskforAngio.com

08/18/2026

We've officially announced the next evolution of cmAngio®.

Building on the first FDA-cleared AI solution for Breast Arterial Calcification (BAC) detection from standard mammograms, cmAngio® 2.0 now quantifies and contextualizes BAC—providing radiologists with objective measurements and meaningful age-based context from the same screening mammogram.

New capabilities include:
✔BAC Quantification – Measures BAC extent in the mammogram.
✔Age-Based BAC Percentile – Compares a patient's BAC findings to the CureMetrix Reference Library of more than 170,000 studies.
✔Age-Based BAC Prevalence – Reports BAC prevalence across women represented in the Reference Library.

As the clinical recognition of BAC continues to accelerate, we're proud to continue advancing cmAngio with capabilities designed to support more consistent, objective BAC assessment.

Read the full announcement here: https://www.einpresswire.com/article/934636644/fda-clears-curemetrix-s-cmangio-2-0-introducing-bac-quantification-and-age-based-context

New release introduces BAC quantification, age-based context, enhanced reporting, and seamless integration.

08/17/2026

cmAngio® 2.0 is now FDA-cleared to Quantify and Contextualize Breast Arterial Calcification (BAC).
From the same screening mammogram, cmAngio provides BAC quantification and age-based context with no additional imaging, radiation, appointments, or workflow disruption.

What's new in 2.0:

✔BAC Quantification. Measures BAC extent in the mammogram.
✔Age-Based BAC Percentile. Compares a patient's BAC findings to the diverse CureMetrix Reference Library of more than 170,000 studies, providing meaningful age-based context for interpretation.
✔Age-Based BAC Prevalence. Reports BAC prevalence, helping physicians better understand BAC prevalence across all women represented in the Reference Library.

This marks an exciting step forward as the role of BAC continues to gain clinical attention.

Learn more at CureMetrix.com.

02/14/2026

Protect the hearts you love. 💕
Happy Valentines day.

02/03/2026

Advancing women’s health—together.
CureMetrix is proud to partner with Rezolut Imaging to bring AI solution for breast arterial calcification (BAC) detection to routine mammography through cmAngio®. This collaboration reflects a shared commitment to expanding the clinical value of breast imaging and turns a routine mammogram into a 2-for-1 exam.
This collaboration aligns with Rezolut’s growing national presence within Envision Radiology and its focus on advancing imaging innovation.
https://www.einpresswire.com/article/889064888/curemetrix-brings-cmangio-bac-detection-to-rezolut-imaging-patients

02/02/2026

Today marks the kickoff of American Heart Month–a time to raise awareness about heart health and the unique risks women face at every stage of life. Heart disease remains the leading cause of death for women in the United States, and risk can begin earlier than many realize, even in your 20s, 30s, and 40s. You’re never too young to start paying attention to your heart health. Learn more from the NIH: https://www.nhlbi.nih.gov/health-topics/education-and-awareness/heart-truth/listen-to-your-heart
At CureMetrix, we are committed to advancing research that enhances the value of routine screening programs worldwide. Our ongoing efforts focus on improved understanding of breast arterial calcifications (BAC) and their potential association with cardiovascular disease (CVD) and chronic kidney disease (CKD), supporting a broader view of women’s health through imaging innovation. You can read more about our latest research here.
https://curemetrix.com/research-heart-health/

National Heart, Lung, and Blood Institute (NHLBI) American Heart Association

11/07/2025

🚀 We’re thrilled to announce that CureMetrix, Inc. has officially joined the Innovators’ Network at the Heart Association Center for Health Technology & Innovation! ❤️💡
This partnership will enable us to:
✅ Collaborate with experts and organizations driving cardiovascular innovation and advancing technology for women’s health.
✅ Leverage evidence-based scientific guidelines to build healthcare tech that truly makes a difference.
✅ Continue our mission of using responsible, science-driven AI to empower clinicians and improve patient outcomes.
Our CEO, Navid Alipour, shared:
“Being part of this network of innovators allows us to collaborate with organizations that share our vision for advancing healthcare through responsible, science-driven AI.”
We’re excited to expand our reach and impact—bringing forward AI innovations that help clinicians and patients every day. Stay tuned for what’s next! 👀📢

10/22/2025

We are at talking about women’s health.

Early breast cancer detection saves lives, and now with CureMetrix cmAngio as the only FDA cleared detecting breast arterial calcification, women get a “2 for 1” benefit from the same mammogram! Now available at hundreds of sites nationwide.

10/08/2025

The convergence of healthcare & hot topic in during DM us if you’d like to meet!